Compare FIVN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | BEAM |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2014 | 2019 |
| Metric | FIVN | BEAM |
|---|---|---|
| Price | $32.90 | $29.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 12 |
| Target Price | $26.06 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 3.4M | 1.7M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | 82.31 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,149,088,000.00 | $24,000.00 |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $10.00 | $33.77 |
| P/E Ratio | $129.20 | ★ N/A |
| Revenue Growth | 10.28 | ★ 33.33 |
| 52 Week Low | $13.29 | $16.03 |
| 52 Week High | $34.58 | $38.26 |
| Indicator | FIVN | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 57.05 |
| Support Level | $17.59 | $28.40 |
| Resistance Level | $34.58 | $34.20 |
| Average True Range (ATR) | 2.01 | 1.34 |
| MACD | -0.10 | 0.47 |
| Stochastic Oscillator | 73.51 | 78.71 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.